

10/522370

5 Rec'd PCT/PTO 25 JAN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : National Phase Entry of PCT/EP2003/008205
Applicant : Karl STANGL et al
Filed : January 25, 2005
TC/A.U. :
Examiner :

Docket No. : 2958-130
Customer No. : 6449
Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By



Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb

New Application

January 25, 2005

Karl STANGL et al

2958-130

7/3/01

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Delete if Known	
				Application Number	New Application 10/522370
				Filing Date	January 25, 2005
				First Named Inventor	Karl STANGL et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	3	Attorney Docket Number	2958-130

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	2.	WO	02 12196	A	Bristol-Myers Squibb Co.	2/14/02	
	3.	WO	98/08825	A1	Procter & Gamble	3/5/98	
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/522370 New Application
				Filing Date	January 25, 2005
				First Named Inventor	Karl STANGL et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	3	of	3	Attorney Docket Number	2958-130

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	4.	DATABASE BIOSIS 'Online', BIOSCIENCES INFORMATION SERVICES, June 2001, Okuno Masataka et al., "Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TFG-beta", Database accession no. PREV200100309222.		
Examiner Signature			Date Considered	